Use of Remdesivir in Patients Hospitalized for COVID-19 Pneumonia: Effect on the Hypoxic and Inflammatory State
Remdesivir is one of the most attractive options for patients with hypoxemic respiratory failure due to coronavirus disease 2019 (COVID-19). The aim of our study was to evaluate the effect of remdesivir on the hypoxic and inflammatory state in patients with moderate to severe COVID-19. We retrospect...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-10-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/15/10/2101 |
| _version_ | 1827719648395657216 |
|---|---|
| author | Alessandro Libra Nicola Ciancio Gianluca Sambataro Enrico Sciacca Giuseppe Muscato Andrea Marino Carlo Vancheri Lucia Spicuzza |
| author_facet | Alessandro Libra Nicola Ciancio Gianluca Sambataro Enrico Sciacca Giuseppe Muscato Andrea Marino Carlo Vancheri Lucia Spicuzza |
| author_sort | Alessandro Libra |
| collection | DOAJ |
| description | Remdesivir is one of the most attractive options for patients with hypoxemic respiratory failure due to coronavirus disease 2019 (COVID-19). The aim of our study was to evaluate the effect of remdesivir on the hypoxic and inflammatory state in patients with moderate to severe COVID-19. We retrospectively enrolled 112 patients admitted for COVID-19 pneumonia, requiring low-flow oxygen, 57 treated with remdesivir plus standard of care (SoC) and 55 treated only with SoC that were similar for demographic and clinical data. We evaluated changes in hypoxemia and inflammatory markers at admission (Day 0) and after 5 days of treatment (Day 5) and the clinical course of the disease. From Day 0 to Day 5, the ratio of arterial oxygen partial pressure to fractional inspired oxygen (P/F) increased from 222 ± 62 to 274 ± 97 (<i>p</i> < 0.0001) in the remdesivir group and decreased from 223 ± 62 to 183 ± 76 (<i>p</i> < 0.05) in the SoC group. Interleukine-6 levels decreased in the remdesivir (45.9 to 17.5 pg/mL, <i>p</i> < 0.05) but not in the SoC group. Remdesivir reduced the need for ventilatory support and the length of hospitalization. In conclusion, compared to standard care, remdesivir rapidly improves hypoxia and inflammation, causing a better course of the disease in moderate to severe COVID-19. |
| first_indexed | 2024-03-10T20:50:04Z |
| format | Article |
| id | doaj.art-9ba8803ebf5f40a6bb09490a5f038251 |
| institution | Directory Open Access Journal |
| issn | 1999-4915 |
| language | English |
| last_indexed | 2024-03-10T20:50:04Z |
| publishDate | 2023-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj.art-9ba8803ebf5f40a6bb09490a5f0382512023-11-19T18:28:19ZengMDPI AGViruses1999-49152023-10-011510210110.3390/v15102101Use of Remdesivir in Patients Hospitalized for COVID-19 Pneumonia: Effect on the Hypoxic and Inflammatory StateAlessandro Libra0Nicola Ciancio1Gianluca Sambataro2Enrico Sciacca3Giuseppe Muscato4Andrea Marino5Carlo Vancheri6Lucia Spicuzza7Regional Referral Centre for Rare Lung Disease, University Hospital “Policlinico-San Marco”, Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, ItalyRegional Referral Centre for Rare Lung Disease, University Hospital “Policlinico-San Marco”, Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, ItalyRegional Referral Centre for Rare Lung Disease, University Hospital “Policlinico-San Marco”, Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, ItalyRegional Referral Centre for Rare Lung Disease, University Hospital “Policlinico-San Marco”, Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, ItalyRegional Referral Centre for Rare Lung Disease, University Hospital “Policlinico-San Marco”, Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, ItalyDepartment of Biomedical and Biotechnological Sciences, Unit of Infectious Diseases, University of Catania, 95123 Catania, ItalyRegional Referral Centre for Rare Lung Disease, University Hospital “Policlinico-San Marco”, Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, ItalyRegional Referral Centre for Rare Lung Disease, University Hospital “Policlinico-San Marco”, Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, ItalyRemdesivir is one of the most attractive options for patients with hypoxemic respiratory failure due to coronavirus disease 2019 (COVID-19). The aim of our study was to evaluate the effect of remdesivir on the hypoxic and inflammatory state in patients with moderate to severe COVID-19. We retrospectively enrolled 112 patients admitted for COVID-19 pneumonia, requiring low-flow oxygen, 57 treated with remdesivir plus standard of care (SoC) and 55 treated only with SoC that were similar for demographic and clinical data. We evaluated changes in hypoxemia and inflammatory markers at admission (Day 0) and after 5 days of treatment (Day 5) and the clinical course of the disease. From Day 0 to Day 5, the ratio of arterial oxygen partial pressure to fractional inspired oxygen (P/F) increased from 222 ± 62 to 274 ± 97 (<i>p</i> < 0.0001) in the remdesivir group and decreased from 223 ± 62 to 183 ± 76 (<i>p</i> < 0.05) in the SoC group. Interleukine-6 levels decreased in the remdesivir (45.9 to 17.5 pg/mL, <i>p</i> < 0.05) but not in the SoC group. Remdesivir reduced the need for ventilatory support and the length of hospitalization. In conclusion, compared to standard care, remdesivir rapidly improves hypoxia and inflammation, causing a better course of the disease in moderate to severe COVID-19.https://www.mdpi.com/1999-4915/15/10/2101remdesivirrespiratory failureantiviral therapyIL6SARS-CoV-2P/F ratio |
| spellingShingle | Alessandro Libra Nicola Ciancio Gianluca Sambataro Enrico Sciacca Giuseppe Muscato Andrea Marino Carlo Vancheri Lucia Spicuzza Use of Remdesivir in Patients Hospitalized for COVID-19 Pneumonia: Effect on the Hypoxic and Inflammatory State Viruses remdesivir respiratory failure antiviral therapy IL6 SARS-CoV-2 P/F ratio |
| title | Use of Remdesivir in Patients Hospitalized for COVID-19 Pneumonia: Effect on the Hypoxic and Inflammatory State |
| title_full | Use of Remdesivir in Patients Hospitalized for COVID-19 Pneumonia: Effect on the Hypoxic and Inflammatory State |
| title_fullStr | Use of Remdesivir in Patients Hospitalized for COVID-19 Pneumonia: Effect on the Hypoxic and Inflammatory State |
| title_full_unstemmed | Use of Remdesivir in Patients Hospitalized for COVID-19 Pneumonia: Effect on the Hypoxic and Inflammatory State |
| title_short | Use of Remdesivir in Patients Hospitalized for COVID-19 Pneumonia: Effect on the Hypoxic and Inflammatory State |
| title_sort | use of remdesivir in patients hospitalized for covid 19 pneumonia effect on the hypoxic and inflammatory state |
| topic | remdesivir respiratory failure antiviral therapy IL6 SARS-CoV-2 P/F ratio |
| url | https://www.mdpi.com/1999-4915/15/10/2101 |
| work_keys_str_mv | AT alessandrolibra useofremdesivirinpatientshospitalizedforcovid19pneumoniaeffectonthehypoxicandinflammatorystate AT nicolaciancio useofremdesivirinpatientshospitalizedforcovid19pneumoniaeffectonthehypoxicandinflammatorystate AT gianlucasambataro useofremdesivirinpatientshospitalizedforcovid19pneumoniaeffectonthehypoxicandinflammatorystate AT enricosciacca useofremdesivirinpatientshospitalizedforcovid19pneumoniaeffectonthehypoxicandinflammatorystate AT giuseppemuscato useofremdesivirinpatientshospitalizedforcovid19pneumoniaeffectonthehypoxicandinflammatorystate AT andreamarino useofremdesivirinpatientshospitalizedforcovid19pneumoniaeffectonthehypoxicandinflammatorystate AT carlovancheri useofremdesivirinpatientshospitalizedforcovid19pneumoniaeffectonthehypoxicandinflammatorystate AT luciaspicuzza useofremdesivirinpatientshospitalizedforcovid19pneumoniaeffectonthehypoxicandinflammatorystate |